1. Home
  2. WINT vs SGD Comparison

WINT vs SGD Comparison

Compare WINT & SGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WINT
  • SGD
  • Stock Information
  • Founded
  • WINT 1992
  • SGD 2021
  • Country
  • WINT United States
  • SGD United States
  • Employees
  • WINT N/A
  • SGD N/A
  • Industry
  • WINT Biotechnology: Biological Products (No Diagnostic Substances)
  • SGD
  • Sector
  • WINT Health Care
  • SGD
  • Exchange
  • WINT Nasdaq
  • SGD Nasdaq
  • Market Cap
  • WINT 2.9M
  • SGD 3.4M
  • IPO Year
  • WINT 1995
  • SGD N/A
  • Fundamental
  • Price
  • WINT $0.31
  • SGD $2.42
  • Analyst Decision
  • WINT Hold
  • SGD
  • Analyst Count
  • WINT 1
  • SGD 0
  • Target Price
  • WINT $7.00
  • SGD N/A
  • AVG Volume (30 Days)
  • WINT 1.2M
  • SGD 117.7K
  • Earning Date
  • WINT 11-27-2024
  • SGD 01-01-0001
  • Dividend Yield
  • WINT N/A
  • SGD N/A
  • EPS Growth
  • WINT N/A
  • SGD N/A
  • EPS
  • WINT N/A
  • SGD N/A
  • Revenue
  • WINT N/A
  • SGD $173,188.00
  • Revenue This Year
  • WINT N/A
  • SGD N/A
  • Revenue Next Year
  • WINT N/A
  • SGD N/A
  • P/E Ratio
  • WINT N/A
  • SGD N/A
  • Revenue Growth
  • WINT N/A
  • SGD N/A
  • 52 Week Low
  • WINT $0.32
  • SGD $1.45
  • 52 Week High
  • WINT $14.75
  • SGD $53.80
  • Technical
  • Relative Strength Index (RSI)
  • WINT 28.66
  • SGD 53.56
  • Support Level
  • WINT $0.33
  • SGD $2.08
  • Resistance Level
  • WINT $0.42
  • SGD $2.56
  • Average True Range (ATR)
  • WINT 0.03
  • SGD 0.22
  • MACD
  • WINT 0.02
  • SGD 0.07
  • Stochastic Oscillator
  • WINT 1.91
  • SGD 91.21

About WINT Windtree Therapeutics Inc.

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

About SGD Safe and Green Development Corporation

Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe & Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partner with third-party equity investors or other developers.

Share on Social Networks: